 |
humanized IgG4 Monoclonal Antibody against total complement component 1, subcomponent s (C1s) |
|---|---|
| Trade Name | |
| Orphan Indication | Bullous pemphigoid |
| USA Market Approval | USA |
| USA Designation Date | 2017-08-17 00:00:00 |
| Sponsor | True North Therapeutics, Inc.;951 Gateway Boulevard;South San Francisco, California, 94080 |
